allergy:drugs:fexofenadine
Fexofenadine
Classification
- Second-Generation H1 Antihistamine
- Selective peripheral H1 receptor inverse agonist
- Active metabolite of terfenadine
Parent class: Histamine & Antihistamines
Mechanism of Action
Fexofenadine selectively blocks peripheral H1 receptors.
Effects:
- ↓ Histamine-mediated vasodilation
- ↓ Capillary permeability
- ↓ Pruritus
- ↓ Sneezing and rhinorrhea
Key Feature:
- Minimal penetration of the blood-brain barrier
- Essentially non-sedating at therapeutic doses
Pharmacologic Background
Fexofenadine is the active metabolite of terfenadine.
Terfenadine was removed from the market due to QT prolongation and torsades risk (CYP3A4 inhibition interactions).
Fexofenadine:
- Does not significantly prolong QT interval
- Does not rely on hepatic metabolism for activation
Pharmacokinetics
- Oral administration
- Onset: ~1 hour
- Duration: ~24 hours
- Primarily eliminated unchanged in feces and urine
- Minimal hepatic metabolism
Absorption reduced by:
- Aluminum/magnesium antacids
- Fruit juices (apple, orange, grapefruit)
Separate dosing from antacids by at least 2 hours.
Indications
- Chronic idiopathic urticaria
- Seasonal allergies
Effective for:
- Sneezing
- Itching
- Rhinorrhea
Less effective for:
- Nasal congestion (intranasal steroids preferred)
Dosing (Adult)
- 60 mg PO twice daily
- OR 180 mg PO once daily
Dose adjustment in renal impairment.
Adverse Effects
Generally very well tolerated.
Possible:
- Headache
- Mild nausea
- Rare dizziness
Sedation:
- Minimal to none
- Lowest sedation risk among common 2nd-generation H1 blockers
Contraindications / Cautions
- Renal impairment (dose adjust)
- Hypersensitivity
Caution:
- Avoid coadministration with fruit juice
- Separate from antacids
Drug Interactions
- Aluminum/magnesium antacids ↓ absorption
- Fruit juice ↓ bioavailability
- Minimal CYP interaction
- No meaningful QT risk at therapeutic doses
Clinical Pearls
- Least sedating of the second-generation H1 blockers.
- Preferred in patients requiring full daytime alertness.
- Safe cardiovascular profile compared to its predecessor (terfenadine).
- Does not significantly impair cognition or psychomotor function.
- Not effective for nasal congestion as monotherapy.
Comparison Within Class
| Drug | Sedation Risk | Elimination | Unique Feature |
|---|---|---|---|
| Loratadine | Very low | Hepatic | Active metabolite = desloratadine |
| Cetirizine | Low | Renal | Slightly more sedating |
| Levocetirizine | Low | Renal | R-enantiomer refinement |
| Fexofenadine | Minimal | Renal/Fecal | Least sedating; safe QT profile |
Related Pages
allergy/drugs/fexofenadine.txt · Last modified: by andrew2393cns
